中樞神經系統治療市場規模、佔有率和成長分析（按疾病、藥物類別、分銷管道和地區）- 產業預測 2025-2032

預計 2023 年 CNS（中樞神經系統）藥物市場價值將達到 1363.7 億美元，並從 2024 年的 1449.6 億美元成長到 2032 年的 2363.3 億美元，預測期內（2025-2032 年）的複合成長率為 6.3%。

全球中樞神經系統 (CNS) 治療市場正在迅速發展，透過廣泛的治療方法治療一系列神經和精神疾病。由於人們對心理健康問題認知的提高和人口老化，該行業正在經歷顯著的成長。正在進行的研究和開發工作正在增強治療方法，而製藥公司和研究機構之間的策略聯盟正在促進創新。隨著技術的不斷進步，中樞神經系統治療市場將有望改善許多人的生活品質。然而，監管挑戰、定價壓力和競爭格局意味著，駕馭複雜的產業格局需要相關人員做出策略性回應。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

中樞神經系統治療市場規模（按疾病和複合年成長率） (2025-2032)

• 市場概況
• 神經血管疾病
• 中樞神經系統創傷
• 心理健康
  • 焦慮症
  • 癲癇
  • 情緒障礙
  • 精神病
  • 其他
• 神經退化性疾病
  • 阿茲海默症
• 帕金森氏症
  • 多發性硬化症
  • 亨丁頓舞蹈症
• 肌萎縮側索硬化症
  • 其他
• 感染疾病
• 中樞神經系統癌症
• 其他

中樞神經系統治療市場規模（依藥物類別和複合年成長率） (2025-2032)

• 市場概況
• 麻醉劑
• 抗驚厥藥
• 止吐藥
• 興奮劑
• 止痛藥
• 其他

中樞神經系統治療市場規模（按分銷管道和複合年成長率） (2025-2032)

• 市場概況
• 醫院藥房
• 零售藥局
• 其他

中樞神經系統治療市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Biogen（United States）
• Otsuka Pharmaceutical Co., Ltd.（Japan）
• Eli Lilly and Company（United States）
• Merck & Co., Inc.（United States）
• AstraZeneca（United Kingdom）
• Takeda Pharmaceutical Company Limited（Japan）
• Novartis AG（Switzerland）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Johnson & Johnson Services, Inc.（United States）
• Pfizer Inc.（United States）
• Sanofi SA（France）
• H. Lundbeck A/S（Denmark）
• UCB SA（Belgium）
• PTC Therapeutics（United States）
• Jazz Pharmaceuticals plc（Ireland）
• Acadia Pharmaceuticals, Inc.（United States）
• Neumora Therapeutics（United States）
• Immunic Therapeutics（United States）
• Muna Therapeutics（Denmark）
• NRG Therapeutics（United Kingdom）

結論和建議

CNS (Central Nervous System) Therapeutics Market size was valued at USD 136.37 billion in 2023 and is poised to grow from USD 144.96 billion in 2024 to USD 236.33 billion by 2032, growing at a CAGR of 6.3% during the forecast period (2025-2032).

The Global Central Nervous System (CNS) Therapeutics market is rapidly evolving, addressing a variety of neurological and psychiatric disorders through an expanding array of treatments. Driven by increased awareness of mental health issues and an aging population, this sector is experiencing significant growth. Ongoing research and development efforts are enhancing therapeutic approaches, while strategic collaborations between pharmaceutical firms and research institutions are fostering innovation. As technological advancements continue, the CNS therapeutics market is poised to improve the quality of life for many individuals. However, challenges such as regulatory hurdles, pricing pressures, and intense competition necessitate strategic responses from industry stakeholders to navigate the complex landscape successfully.

Top-down and bottom-up approaches were used to estimate and validate the size of the CNS (Central Nervous System) Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

CNS (Central Nervous System) Therapeutics Market Segments Analysis

Global CNS (Central Nervous System) Therapeutics Market is segmented by Disease, Drug Class, Distribution Channel and region. Based on Disease, the market is segmented into Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer and Others. Based on Drug Class, the market is segmented into Anesthetics, Anticonvulsants, Antiemetics, CNS Stimulants, Pain Relievers and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the CNS (Central Nervous System) Therapeutics Market

The global aging population is a key driver for the Central Nervous System (CNS) therapeutics market, as an increase in age correlates with a higher incidence of neurological disorders such as Alzheimer's and Parkinson's disease. This demographic transformation creates a substantial demand for effective CNS treatments and therapies, given that elderly individuals face a greater risk of developing these debilitating conditions. Consequently, the growing prevalence of age-related neurological disorders underscores the urgent need for innovative CNS therapeutics, prompting advancements in research and development to address the healthcare challenges associated with this rising population segment.

Restraints in the CNS (Central Nervous System) Therapeutics Market

The Central Nervous System (CNS) Therapeutics market faces significant restraints primarily due to the complex nature of developing drugs and treatments for neurological and psychiatric disorders. The process necessitates extensive clinical trials and encounters multiple regulatory challenges, resulting in considerable scrutiny from authorities. This rigorous oversight can cause substantial delays in the approval process and escalate costs associated with bringing new therapies to market. Consequently, these barriers hinder not only innovation within the field but also restrict timely access for patients seeking effective treatments, ultimately impacting the overall progress and availability of CNS therapeutics.

Market Trends of the CNS (Central Nervous System) Therapeutics Market

The Central Nervous System (CNS) therapeutics market is witnessing a significant shift towards personalized medicine, driven by advancements in genetics and neuroimaging technologies. This trend enables healthcare providers to tailor treatments to individual patients based on their unique genetic profiles and neurobiological characteristics, resulting in more precise and effective interventions. By focusing on personalized approaches, the market aims to improve treatment outcomes for prevalent CNS disorders such as Alzheimer's, depression, and schizophrenia while reducing adverse effects associated with traditional therapies. As this paradigm evolves, it holds the potential to transform the landscape of CNS therapeutics, enhancing patient care and efficacy.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global CNS (Central Nervous System) Therapeutics Market Size by Disease & CAGR (2025-2032)

• Market Overview
• Neurovascular Diseases
• CNS Trauma
• Mental Health
  • Anxiety Disorders
  • Epilepsy
  • Mood Disorders
  • Psychotic Disorders
  • Others
• Neurodegenerative Diseases
  • Alzheimer's Disease
• Parkinsosn's Disease
  • Multiple Sclerosis
  • Huntington's Disease
• Amytrophic Lateral Sclerosis
  • Others
• Infectious Diseases
• CNS Cancer
• Others

Global CNS (Central Nervous System) Therapeutics Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Anesthetics
• Anticonvulsants
• Antiemetics
• CNS Stimulants
• Pain Relievers
• Others

Global CNS (Central Nervous System) Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Others

Global CNS (Central Nervous System) Therapeutics Market Size & CAGR (2025-2032)

• North America (Disease, Drug Class, Distribution Channel)
  • US
  • Canada
• Europe (Disease, Drug Class, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease, Drug Class, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease, Drug Class, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease, Drug Class, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Biogen (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PTC Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jazz Pharmaceuticals plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acadia Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neumora Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immunic Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Muna Therapeutics (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NRG Therapeutics (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations